| URL | https://endpts.com/building-on-crispr-success-inte |
| Source | Endpoints News |
| Date Published | 02/23/2022 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Intellia |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2022 |
| Domestically, the work will be done: | In-house |
| City reshored to: | Waltham |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | CRISPR-based therapies |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market, Skilled workforce availability/training, Under-utilized capacity |